HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Co-Diagnostics (CODX) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Class Action Filed
SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Co-Diagnostics, Inc. (NASDAQ: CODX) investors who suffered significant losses to submit your losses now .
- SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Co-Diagnostics, Inc. (NASDAQ: CODX) investors who suffered significant losses to submit your losses now .
- The complaint alleges that Defendants failed to disclose that demand for the Test had plummeted throughout the second quarter ended June 30, 2022.
- As a result, Defendants positive statements about the demand for the Logix Smart COVID-19 Test lacked a reasonable basis.
- Were focused on investors losses and proving Defendants misled investors about the real demand for Co-Diagnostics test, said Reed Kathrein, the Hagens Berman partner leading the investigation.